Printer Friendly

GLAXO INC., HOUGHTEN PHARMACEUTICALS SIGN JOINT RESEARCH, DEVELOPMENT AGREEMENT USING PATENTED PEPTIDE TECHNOLOGY IN DRUG DISCOVERY

GLAXO INC., HOUGHTEN PHARMACEUTICALS SIGN JOINT RESEARCH, DEVELOPMENT
 AGREEMENT USING PATENTED PEPTIDE TECHNOLOGY IN DRUG DISCOVERY
 SAN DIEGO, Aug. 31 /PRNewswire/ -- Glaxo Inc. and Houghten Pharmaceuticals Inc. (HPI) today announced they have signed a joint research and development agreement involving the use of HPI's patented peptide screening technology to speed drug discovery.
 Under the terms of the agreement, Glaxo will use HPI's synthetic peptide libraries for screening activity in a number of therapeutic areas. The peptide combinatorial library (PCL) technology developed by HPI provides for the rapid screening of peptides for desired interactions with specified receptor molecules.
 Specific terms of the agreement were not disclosed. However, Dr. Richard Houghten, chairman, chief executive officer and founder of HPI, said the joint research and development collaboration provides both companies an opportunity to identify and develop lead compounds for various disease treatments. Under the terms of the agreement, HPI will retain rights to peptides discovered and developed while Glaxo will use information discovered in the research to develop non-peptide medicines. The agreement provides for both initial and milestone payments to HPI. Glaxo and HPI will each receive royalties based on sales of products resulting from the collaboration.
 Founded in 1990, HPI is using a variety of peptides as chemical screening molecules to discover and develop its own portfolio of proprietary pharmaceuticals. In addition HPI licenses the peptide libraries to biopharmaceutical partners outside its strategic business focus. Through its wholly owned subsidiary, Multiple Peptide Systems, HPI offers custom peptides and related products to more than 1,000 research laboratories throughout the world as well as good manufacturing practices (GMP) synthesis capability.
 Glaxo Inc., based in Research Triangle Park, is the nation's second-largest research-based pharmaceutical firm. A subsidiary of London-based Glaxo Holdings p.l.c. (NYSE: GLX), it researches, develops, manufactures and markets prescription medicines for the treatment of gastrointestinal, respiratory, central nervous system, cardiovascular and infectious diseases, as well as diseases of the skin. Through its Glaxo Inc. Research Institute, the company is Glaxo's worldwide research center in the areas of cancer, inflammation and metabolic diseases.
 HPI is a world leader in research and development involving the use of peptides in drug discovery. Its mission is to develop novel drug therapies for infectious, inflammatory and hypersensitivity diseases based on lead compounds discovered by its patented PCL technology. Corporate offices, laboratories and manufacturing facilities are in Torrey Pines Business and Research Park, San Diego.
 -0- 8/31/92
 /CONTACT: Tom Gable or Julie Smutko of The Gable Group, 619-234-1300, for Houghten Pharmaceuticals/ CO: Glaxo Inc.; Houghten Pharmaceuticals Inc. ST: California IN: MTC SU:


LS-JL -- SD002 -- 4817 08/31/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:437
Previous Article:WORLDWIDE FOREST PRODUCTS WINS SUPPLY CONTRACT FOR DALLAS LIGHT RAIL SYSTEM
Next Article:STEIN MART ANNOUNCES ELECTION OF ROBERT D. DAVIS TO BOARD OF DIRECTORS
Topics:


Related Articles
BIOCHEM AND GLAXO CONCLUDE AGREEMENT ON ANTI-CANCER COMPOUNDS
BIOCHEM AND GLAXO CONCLUDE AGREEMENT ON ANTI-CANCER COMPOUNDS
P&G AND HOUGHTEN PHARMACEUTICALS INC. SIGN JOINT RESEARCH AGREEMENT
GLAXO AND LIGAND PHARMACEUTICALS TO ESTABLISH DRUG DEVELOPMENT RESEARCH PROGRAM FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
AMERICAN CYANAMID, HOUGHTEN PHARMACEUTICALS SIGN RESEARCH COLLABORATION AGREEMENT
AMYLIN PHARMACEUTICALS AND GLAXO-WELLCOME ANNOUNCE DISCONTINUANCE OF RESEARCH & DEVELOPMENT COLLABORATION
DURA PHARMACEUTICALS, INC. SIGNS COLLABORATIVE AGREEMENT WITH HOUGHTEN PHARMACEUTICALS, INC.
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
Trega Biosciences and TPIMS Extend Combinatorial Chemistry Agreement
Trega Biosciences and Torrey Pines Institute for Molecular Studies To Discontinue Research Collaboration

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters